• Vaccine Name: Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine
• Target Pathogen: Actinobacillus pleuropneumoniae
• Target Disease: porcine pleuropneumonia
• Type: Live, attenuated vaccine
• Status: Research
• apxIIIB gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• apxIIID gene engineering:
  • Type: Gene mutation
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: An apxIIIBD mutant (1536∆B∆D) was selected and the correct mutation was verified by PCR using three primer pairs. The X3BD-F2 and X3BD-R2 primer pair was designed to produce products of 3720 and 4365 bps from the wild-type 1536 and 1536∆B∆D genomes, respectively (Park et al., 2009).
• Immunization Route: intranasal immunization

Pig Response

• Persistence: The LD50 of 1536∆B∆D in mice was 6.9 x 10^8 CFU, while that of the wild-type was 4.0 x 10^8 CFU, showing that the mutation of the apxIIIBD genes attenuates the lethality of A. pleuropneumoniae in mice (Park et al., 2009).
• Efficacy: To evaluate the ability of the mutant 1536∆B∆D strain to protect mice against lethal challenge, mice were immunized with 1536∆B∆D twice and challenged with a lethal dose of wild-type A. pleuropneumoniae 1536. Eight of the nine mice immunized with 1536∆B∆D survived for more than 72 hr after lethal challenge (89% protection), while all eight of the unimmunized mice died by 72 hr after challenge (Park et al., 2009).